Abstract
Although cohort studies which are based on intention-to-treat (ITT) approach offer a simple design with data which are simpler to analyse and results easier to interpret, such studies also intrinsically assume that any time-varying treatment effect that exits can be adequately estimated by a fixed-effect component. However, such an assumption may not reflect real-life drug use. Reflection of real-life clinical practice is a major strength of epidemiologic safety studies. The failure to properly reflect reality may result in effect under-estimation leading to false and irreproducible conclusions due to exposure misclassification. In effect, the use of nested case-control design is a concession that ITT in cohort design may not be adequate. But the nested design also has its own sources of bias, including confounding by indication. We present an overview of the counter-matched version of the nested case-control, case-crossover, case-in-time, case series and case-cohort designs as alternatives in prospective post-authorization safety studies.
Keywords: Cohort study, selection bias, case-control design, counter-matching
Current Drug Safety
Title: How Real is Intention-To-Treat (ITT) Analysis in Non-Interventional Post Authorization Safety Studies? We Can Do Better
Volume: 4 Issue: 2
Author(s): Victor A. Kiri and Gilbert MacKenzie
Affiliation:
Keywords: Cohort study, selection bias, case-control design, counter-matching
Abstract: Although cohort studies which are based on intention-to-treat (ITT) approach offer a simple design with data which are simpler to analyse and results easier to interpret, such studies also intrinsically assume that any time-varying treatment effect that exits can be adequately estimated by a fixed-effect component. However, such an assumption may not reflect real-life drug use. Reflection of real-life clinical practice is a major strength of epidemiologic safety studies. The failure to properly reflect reality may result in effect under-estimation leading to false and irreproducible conclusions due to exposure misclassification. In effect, the use of nested case-control design is a concession that ITT in cohort design may not be adequate. But the nested design also has its own sources of bias, including confounding by indication. We present an overview of the counter-matched version of the nested case-control, case-crossover, case-in-time, case series and case-cohort designs as alternatives in prospective post-authorization safety studies.
Export Options
About this article
Cite this article as:
Kiri A. Victor and MacKenzie Gilbert, How Real is Intention-To-Treat (ITT) Analysis in Non-Interventional Post Authorization Safety Studies? We Can Do Better, Current Drug Safety 2009; 4 (2) . https://dx.doi.org/10.2174/157488609788173008
DOI https://dx.doi.org/10.2174/157488609788173008 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanomedicines for Brain Targeting: A Patent Review
Recent Patents on Nanomedicine Clinical Trials for Neuroprotection in ALS
CNS & Neurological Disorders - Drug Targets Editorial: [Hot Topic: Central Nervous System Drugs in the Treatment of Neurological Disorders]
Central Nervous System Agents in Medicinal Chemistry University of Kentucky Sanders-Brown Healthy Brain Aging Volunteers: Donor Characteristics, Procedures and Neuropathology
Current Alzheimer Research Syphilis and HIV Co-Infection: When is Lumbar Puncture Indicated?
Current HIV Research Kynurenine Pathway and Disease: An Overview
CNS & Neurological Disorders - Drug Targets Anti-Inflammatory and Anti-Allergy Drugs in Rhinosinusitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Identification of Antibacterial Molecule(s) from Animals Living in Polluted Environments
Current Pharmaceutical Biotechnology Drug Target Discovery Through Analysis of Laccase Regulatory Networks of Cryptococccus neoformans
Current Enzyme Inhibition Targeting the Chemokine Receptor CXCR3 and Its Ligand CXCL10 in the Central Nervous System: Potential Therapy for Inflammatory Demyelinating Disease?
Current Neurovascular Research Desferrioxamine as Immunomodulatory Agent During Microorganism Infection
Current Pharmaceutical Design Integrase Strand Transfer Inhibitors and the Emergence of Immune Reconstitution Inflammatory Syndrome (IRIS)
Current HIV Research Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience The Antibiotic Potential of Prokaryotic IMP Dehydrogenase Inhibitors
Current Medicinal Chemistry Amine Oxidase Inhibitors and Development of Neuroprotective Drugs
Current Neuropharmacology Cerebral White Matter Injuries Following a Hypoxic/Ischemic Insult During the Perinatal Period: Pathophysiology, Prognostic Factors, and Future Strategy of Treatment Approach. A Minireview
Current Pharmaceutical Design Nanoparticles in the Pharmaceutical Industry and the Use of Supercritical Fluid Technologies for Nanoparticle Production
Current Drug Delivery Mast Cell – Glia Dialogue in Chronic Pain and Neuropathic Pain: Blood-Brain Barrier Implications
CNS & Neurological Disorders - Drug Targets